BMRN vs DSP · P/E 40, rev $2.85B vs P/E 30, rev $289.2M
Biomarin Pharmaceutical Inc (BMRN) versus Viant Technology Inc (DSP) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Viant Technology Inc (DSP) is a software - application company listed on US.
Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported DSP revenue for 2024-12-31 was $289.2M. Net income was $12.5M. Revenue was up 29.7% from 2023-12-31 to 2024-12-31. DSP currently screens at market cap $794.6M and trailing P/E 30.3.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. DSP currently screens at market cap $794.6M and trailing P/E 30.3.
Not investment advice. Open the BMRN and DSP stock pages for the full models.
Not investment advice.